Curitiba, Brazil, November 13, 2018 – IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy solutions and radiation therapy integrated quality assurance (QA) for the treatment of cancer, announces the first clinical implementation of Dolphin Patient QA solution in Brazil.
With the use of Dolphin, the radiation therapy team at the Radion Institute implemented a new quality assurance standard for challenging radiation therapy and Stereotactic Body Radiation Therapy (SBRT) cases. To bring patient safety to a new level in Brazil, the hospital’s team can now review treatment doses using Dolphin’s 3D dose verification within the patient’s individual anatomy.
"Patient safety and confidence in treatment accuracy are the main reasons for clinically implementing Dolphin at our institution”, said Dr. José Carlos Gasparin Pereira, Radiation Oncologist and Director of Radiotherapy at Radion. “We are now able to detect even minimal deviation between the treatment plan and the radiation beams for each individual patient, allowing us to define corrective actions without distracting from the patient's treatment. This allows us to offer a new standard of quality and safety to our patients."
Alongside Dolphin, Radion Institute also implemented IBA Dosimetry’s myQA global QA platform to streamline all quality assurance modalities in one solution.
"We needed a quality assurance tool that would keep up with latest treatment delivery trends. With Dolphin, advanced treatments such as VMAT, SBRT and cranial radiosurgery can be measured and evaluated quickly and efficiently”, said Ricardo Goulart, Physicist at the Radion Institute. “The seamless integration of Dolphin as well as myQA machine tests allowed us to implement a state of the art QA program without difficulties.”
“We are very impressed by the work achieved by the team at Radion Institute and we are very proud to be partners, to contribute to quality assurance and patient safety at the highest standards in Brazil,” said Jean-Marc Bothy, President of IBA Dosimetry GmbH.
To find out more please visit iba-dosimetry.com
About IBA Dosimetry
IBA Dosimetry GmbH innovates radiation therapy, proton therapy and diagnostic imaging through integrated Quality Assurance solutions that are efficient, intuitive and that provide peace of mind for healthcare professionals and patients around the world. The myQA® Global QA Platform is the backbone for Integrated Quality Assurance solutions. IBA Dosimetry has more than 220 international employees in four offices in Germany, France, China and USA.
Find more information at: iba-dosimetry.com
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: iba-worldwide.com
About the Radion Institute
With core values of experience, modernity and a focus on more humanized care; the Radion Oncology Institute represents a new concept in cancer treatment in both Paraná and Brazil, serving private patients as well as patients with health plans. Services offered by Radion include three-dimensional External Radiotherapy, VMAT with IGRT 3D and 4D, frameless Cranial Radiosurgery, Cranial Stereotactic Radiotherapy, SBRT, 3D Gynecological High-Dose Rate (HDR) Brachytherapy, three-dimensional Prostate Brachytherapy with HDR and Low-Dose Rate (LDR), Three-Dimensional Prostate (LDR) using 125-iodine seeds, as well as rescue in prostatic tumors relapsed post-radiotherapy.
More information can be found at: http://institutoradion.com.br/
Media Contact:
Ralf Schira
Director Global Marketing
IBA Dosimetry,
ralf.schira@iba-group.com